Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit

Executive Summary

FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians

You may also be interested in...

Advertising Regulation Wiki? Industry Wants Authoritative But Frequently Updated FDA Guidance (And/Or Regs) On Internet Drug Promotion

It's up to FDA now to outline a "how-to" for drug makers when it comes to using the Internet and social media for drug promotion - with guidance, regulations or both. But drug makers made evident in comments on the agency's meeting last fall that FDA also must determine how to account for changing technologies

Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs

Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product

Who's Liable For Online Content? Pharma, Marketers Disagree (Slightly)

Compensation and collaboration - as well as creation - should be the triggers for determining a pharmaceutical company's liability for Internet content, Rohit Bhargava of Ogilvy 360 Digital Influence advised FDA during a Nov. 12-13 hearing on promoting medical products on the Internet and in social media

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts